Historical source-based research. Compilation date and financial period are different dates.

Research summary

A research framework for 12 covered healthcare issuers, with explicit attention to financial comparability.

Industry context

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Covered sample

LLY, JNJ, ABBV, MRK, NVS, AZN, AMGN, GILD, ABT, PFE, ISRG, VRTX. Selection favors available recent annual USD disclosures; it is not a market-cap ranking.

Financial evidence

The related sector data notes provide company-level observations for revenue growth, profitability, cash conversion and balance-sheet structure. They show the exact sample and period for every calculation.

Valuation context

Company profiles show eligible dated valuation ratios using the September 17, 2026 price snapshot and selected annual accounting denominators. Capitalization-based measures use estimates and are identified as such. These are not live, TTM or forward values. A historical-multiple series and EV/EBITDA are not available. Sector medians describe a selected sample; they do not establish fair value or expected returns.

Risks and uncertainties

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

What to monitor

Product concentration, research investment, utilization, reimbursement and cash generation.

Sources & dates

Methodology protocol ↗SMS research updates ↗